Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells

Li, Fengqiao; Mei, Hao; Xie, Xiaodong; Zhang, Huijuan; Liu, Jian; Lv, Tingting; Nie, Huifang; Gao, Yu; Lee, Jia

doi:10.1208/s12248-017-0057-9

Cited by 51 publications

(24 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Typically, aptamers are attached to liposomes using covalent bonding (preconjugation to lipids) or a post-insertion method. Covalent bonding techniques commonly employ 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) chemistry and thiol-maleimide linkage reactions [98][99][100][101]. The post-insertion method reacts functional group-activated lipids to aptamers to create unstable micelles, which are then mixed with preformed liposomes to incorporate the aptamer-lipids into the liposome membrane [97,102,103].…”

Section: Aptamer-liposome Bioconjugatesmentioning

confidence: 99%

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

et al. 2020

View full text Add to dashboard Cite

In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug carrier, and the only NP system currently approved by the FDA for clinical use, owing to their advantageous physicochemical properties and excellent biocompatibility. Recent advances in liposome technology have been focused on bioconjugation strategies to improve drug loading, targeting, and overall efficacy. In this review, we highlight recent literature reports (covering the last five years) focused on bioconjugation strategies for the enhancement of liposome-mediated drug delivery. These advances encompass the improvement of drug loading/incorporation and the specific targeting of liposomes to the site of interest/drug action. We conclude with a section highlighting the role of bioconjugation strategies in liposome systems currently being evaluated for clinical use and a forward-looking discussion of the field of liposomal drug delivery.

show abstract

Section: Aptamer-liposome Bioconjugatesmentioning

confidence: 99%

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[ 1 ] In general, lung cancers are broadly classified into small cell lung cancer (SCLC) and non‐small cell lung cancer (NSCLC) according to their histological appearance, with the latter comprising about 85% of total cases. [ 2 ] Currently, conventional chemotherapy is the mainstay of treatment for NSCLC, but its effectiveness remains marginal. [ 3 ] To cope with the low survival rate of NSCLC, alternative treatment approaches such as molecular‐targeted therapies have been extensively explored.…”

Section: Introductionmentioning

confidence: 99%

An Activatable Nano‐Prodrug for Treating Tyrosine‐Kinase‐Inhibitor‐Resistant Non‐Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging

Xie

Zhan

Wang

et al. 2020

Small

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase protein, and constitutive activation of EGFR has been shown to be related to cancer initiation, progression, and poor prognosis in several cancers including NSCLC. [5] The EGFR-targeted inhibitors, such as tyrosine kinase inhibitors (TKIs) (e.g., gefitinib (GEF) and erlotinib), have been developed and proved to treat advanced NSCLC, especially the lung adenocarcinoma (a subset of NSCLC). [6] Upon binding to the EGFR tyrosine kinase domain, these small molecular inhibitors can block the phosphorylation of EGFR and activation of some downstream pathways. The use of TKIs significantly increases patient prognosis and prolongs the progression-free survival with less side effect, [7] yet curative effects are usually compromised due to the occurrence of intrinsic and/or acquired resistance. [8] Activation of EGFR results in activation of several downstream signaling pathways, such as phosphatidylinositol 3-kinase/serine threonine protein kinase (PI3K/Akt) and mitogen-activated protein kinase kinase/extracellular receptor kinase (MEK/ERK) pathways, which play major roles in proliferation, survival, and drug resistance in many different cell types. [9] There is accumulating evidence that PI3K/Akt signaling is essential for mediating EGFR survival signals in NSCLC, and persistent activation of the Akt signaling has been associated with resistance to several TKIs including gefitinib in NSCLC. [10] Thus, inhibiting PI3K/Akt pathway can restore the sensitivity of NSCLC cells to TKIs and thereby reduce the resistance of NSCLC cells to TKIs therapy. [11] Indeed, recent studies reveal that the PI3K/Akt pathway inhibition along with EGFR suppression is beneficial to NSCLC treatment. [12] There results prompted us to search for an alternative formulation that can treat the TKI-resistant NSCLC effectively. Celastrol (CEL), a naturally occurring quinone methide triterpene derived from Tripterygium wilfordii, is a pleiotropic compound and has been used for treating multiple diseases including cancers. [13] A number of studies indicate that celastrol inhibits tumor cell proliferation and promotes apoptosis through significant suppression of PI3K/Akt signaling. [14] This property makes celastrol a potent component in treatment of TKI-resistant NSCLC. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the cause of high rate of mortality. The epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors are used to treat NSCLC, yet their curative effects are usually compromised by drug resistance. This study demonstrates a nanodrug for treating tyrosine-kinase-inhibitor-resistant NSCLC through inhibiting upstream and downstream EGFR signaling pathways. The main molecule of the nanodrug is synthesized by linking a tyrosine kinase inhibitor gefitinib and a near-infrared dye (NIR) on each side of a disulfide via carbonate bonds, and the nanodrug is then obtained through nanoparticle formation of the main molecule in a...

show abstract

“…To overcome drug resistance from erlotinib, Li et al developed lung cancer-specific liposomes using EGFR aptamer-chitosan conjugates to deliver erlotinib to the tumor. 60 The nanocarrier showed good biostability and binding specificity for EGFR-mutated cancer cells, which facilitated liposomal erlotinib internalization into EGFR-mutated cancer cells. Aptamer-modified liposomes exhibited better delivery of erlotinib to EGFRmutated cancer cells than standard delivery techniques, which resulted in greater cytotoxicity.…”

Section: Nanoparticles Liposomesmentioning

confidence: 98%

<p>Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications</p>

Guan¹,

Zhang²

2020

IJN

View full text Add to dashboard Cite

Aptamers are a class of targeting ligands that bind exclusively to biomarkers of interest. Aptamers have been identified as candidates for the construction of various smart systems for therapy, diagnosis, bioimaging, and drug delivery due to their high target affinity and specificity. Aptamers are accounted as chemical antibodies that can be readily linked to drugs, sensors, signal enhancers, or nanocarriers for functionalization. Use of aptamer-guided medications, especially nanomedicines, has resulted in encouraging outcomes compared to those use of aptamer-free counterparts. This article reviews recent advances in the use of aptamers as targeting ligands for various biomedical and pharmaceutical purposes. Special interests focus on aptamer-based theranostics, biosensing, bioimaging, drug potentiation, and targeted drug delivery.

show abstract

Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells

Cited by 51 publications

References 60 publications

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

An Activatable Nano‐Prodrug for Treating Tyrosine‐Kinase‐Inhibitor‐Resistant Non‐Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging

<p>Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications</p>

Contact Info

Product

Resources

About